Inventiva S.A.
IVA.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$760.63M
Close$
$-0.14
104.8% downside
Current Fair Value
104.8% downsideOvervalued by 104.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $760.63 Million |
|---|---|
| Enterprise Value | $661.20 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.9 |
| Beta | 0.92 |
| Outstanding Shares | 273,582,870 |
Return
| Return on Equity | -946.81% |
|---|---|
| Return on Assets | -222.38% |
| Return on Invested Capital | -234.76% |
Valuation & Multiples
| P/E Ratio | -5.4 |
|---|---|
| PEG | 9 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 61.28 |
| Enterprise Value to EBIT | -1.51 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 1.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 28, 2026
EPS Estimate
$-0.37
Average shareholder expectationRevenue Estimate
$2.50 M
Average shareholder expectationNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
$4.16 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Inventiva
77 employees
CEO: Frederic Cren Inventiva S.A. is a clinical-stage biopharmaceutical firm dedicated to developing oral small molecule therapies. Its primary therapeutic focus areas include non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various o...